Insurance Coverage Differs by Demographics, Cancer Type
the Cancer Therapy Advisor take:
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage, according to an article published online in the journal Cancer.
Participants of this study included 688,794 patients between the ages of 18 to 64 years with a diagnosis of one of the top 25 incident cancers between 2007 and 2010 in the Surveillance, Epidemiology, and End Results (SEER) database.
The patients were analyzed based on characteristics, such as age, race, sex, marital status, residency, and county-level demographics (e.g., percent poverty level). The individual’s insurance status was determined to be non-Medicaid insurance, Medicaid coverage, or no insurance.
Results showed nonwhite, younger age males, unmarried, residence in counties with higher levels of poverty, and rural residence were associated with being uninsured versus having non-Medicaid insurance (all P<0.001).
Patients with prostate cancer, melanoma, and thyroid cancer had the highest non-Medicaid insurance rates (92.3%, 92.5%, and 89.5%, respectively), while patients with cervical, liver, and stomach cancer had the lowest rates of non-Medicaid insurance (64.2%, 67.9%, 70.9%, respectively;P<0.001).
The majority of uninsured patients reported cases of lung cancer (14.9%), colorectal cancer (12.1%), and breast cancer (10.2%) (all P<0.001).
Lung cancer was found to cause the majority of cancer mortality across all insurance categories.
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Warburg Effect: Can Cancer Be Starved of Sugar?
- Does Radiotherapy Lead to An In Situ Breast Cancer Vaccine?
- Proinflammatory Diet and Colorectal Cancer
- Surgery May Be Superior to Stereotactic Body Radiation Therapy for Early Stage NSCLC
- Smoking After Diagnosis Leads to Worse Renal Cell Carcinoma-specific Survival
- Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma
- Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma
- Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma
- Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma
- Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer